Claire M. Perks

4.6k total citations
125 papers, 3.6k citations indexed

About

Claire M. Perks is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Claire M. Perks has authored 125 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Molecular Biology, 63 papers in Endocrinology, Diabetes and Metabolism and 54 papers in Cancer Research. Recurrent topics in Claire M. Perks's work include Growth Hormone and Insulin-like Growth Factors (61 papers), Cancer, Hypoxia, and Metabolism (40 papers) and Metabolism, Diabetes, and Cancer (32 papers). Claire M. Perks is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (61 papers), Cancer, Hypoxia, and Metabolism (40 papers) and Metabolism, Diabetes, and Cancer (32 papers). Claire M. Perks collaborates with scholars based in United Kingdom, United States and Malaysia. Claire M. Perks's co-authors include Jeff M.P. Holly, Paul V. Newcomb, Kalina Biernacka, Catherine McCaig, Jeffrey M P Holly, D.C. Wathes, Amit Bahl, J.M.P. Holly, P.V. Newcomb and Li Zeng and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Claire M. Perks

124 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Claire M. Perks United Kingdom 34 1.8k 1.6k 1.1k 724 426 125 3.6k
Toshiji Saibara Japan 39 1.3k 0.7× 1.8k 1.1× 491 0.4× 569 0.8× 354 0.8× 169 6.4k
Vittorio Colantuoni Italy 42 2.8k 1.5× 606 0.4× 736 0.7× 881 1.2× 639 1.5× 124 4.6k
Norman C.W. Wong Canada 42 2.9k 1.6× 1.4k 0.9× 511 0.5× 701 1.0× 1.1k 2.5× 144 5.5k
Elvira Haas Switzerland 22 1.2k 0.6× 452 0.3× 818 0.7× 466 0.6× 602 1.4× 35 2.8k
Tomomi Fujisawa Japan 33 1.0k 0.6× 986 0.6× 354 0.3× 672 0.9× 1.1k 2.5× 169 3.9k
Zemin Yao Canada 45 2.6k 1.4× 1.6k 1.0× 856 0.8× 551 0.8× 253 0.6× 115 6.7k
Samuele De Minicis Italy 39 1.8k 1.0× 1.1k 0.7× 429 0.4× 565 0.8× 257 0.6× 57 7.1k
Salvatore Mancuso Italy 40 1.6k 0.8× 386 0.2× 373 0.3× 1.0k 1.4× 536 1.3× 149 5.1k
Giulia Chiesa Italy 35 1.5k 0.8× 1.1k 0.7× 760 0.7× 274 0.4× 406 1.0× 114 4.5k
Mary G. Sorci‐Thomas United States 38 1.8k 1.0× 1.2k 0.7× 559 0.5× 535 0.7× 231 0.5× 85 4.4k

Countries citing papers authored by Claire M. Perks

Since Specialization
Citations

This map shows the geographic impact of Claire M. Perks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire M. Perks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire M. Perks more than expected).

Fields of papers citing papers by Claire M. Perks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire M. Perks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire M. Perks. The network helps show where Claire M. Perks may publish in the future.

Co-authorship network of co-authors of Claire M. Perks

This figure shows the co-authorship network connecting the top 25 collaborators of Claire M. Perks. A scholar is included among the top collaborators of Claire M. Perks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire M. Perks. Claire M. Perks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Barker, Rachel, et al.. (2024). Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease. Clinical Science. 138(21). 1357–1369. 2 indexed citations
3.
Biernacka, Kalina, et al.. (2024). The Role of Insulin-like Growth Factor Binding Protein (IGFBP)-2 in DNA Repair and Chemoresistance in Breast Cancer Cells. Cancers. 16(11). 2113–2113. 2 indexed citations
4.
Fang, Si, James Yarmolinsky, Dipender Gill, et al.. (2023). Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS Medicine. 20(1). e1003988–e1003988. 30 indexed citations
5.
Kataoka, Naoyuki, et al.. (2023). The IGF-Independent Role of IRS-2 in the Secretion of MMP-9 Enhances the Growth of Prostate Carcinoma Cell Line PC3. International Journal of Molecular Sciences. 24(20). 15065–15065. 1 indexed citations
6.
7.
Lay, Abigail C., Lorna J. Hale, Robert J. P. Pope, et al.. (2021). IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes. Diabetologia. 64(7). 1690–1702. 25 indexed citations
8.
Challapalli, Amarnath, Paul White, S.K. Pearson, et al.. (2021). A Single-arm Phase II Trial of Neoadjuvant Cabazitaxel and Cisplatin Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Urinary Bladder. Clinical Genitourinary Cancer. 19(4). 325–332. 4 indexed citations
9.
Ward, Douglas G., et al.. (2021). The Sirenic Links between Diabetes, Obesity, and Bladder Cancer. International Journal of Molecular Sciences. 22(20). 11150–11150. 23 indexed citations
10.
Martin, Richard M., Claire M. Perks, Claire Kelly, et al.. (2021). Could Reducing Body Fatness Reduce the Risk of Aggressive Prostate Cancer via the Insulin Signalling Pathway? A Systematic Review of the Mechanistic Pathway. Metabolites. 11(11). 726–726. 1 indexed citations
11.
12.
Zielińska, Hanna, Ahmad Al-Ghamdi, Amit Bahl, et al.. (2020). Interaction between GRP78 and IGFBP-3 Affects Tumourigenesis and Prognosis in Breast Cancer Patients. Cancers. 12(12). 3821–3821. 18 indexed citations
13.
Penfold, Chris, Claire M. Perks, Jeff M.P. Holly, et al.. (2019). Phase II randomised control feasibility trial of a nutrition and physical activity intervention after radical prostatectomy for prostate cancer. BMJ Open. 9(11). e029480–e029480. 10 indexed citations
14.
Tan, Vanessa Y., Kalina Biernacka, Tom Dudding, et al.. (2018). Reassessing the Association between Circulating Vitamin D and IGFBP-3: Observational and Mendelian Randomization Estimates from Independent Sources. Cancer Epidemiology Biomarkers & Prevention. 27(12). 1462–1471. 6 indexed citations
15.
Lewis, Sarah J., Mike Gardner, Julian P. T. Higgins, et al.. (2017). Developing the WCRF International/University of Bristol Methodology for Identifying and Carrying Out Systematic Reviews of Mechanisms of Exposure–Cancer Associations. Cancer Epidemiology Biomarkers & Prevention. 26(11). 1667–1675. 30 indexed citations
16.
Rosendahl, Ann H., Claire M. Perks, Li Zeng, et al.. (2015). Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer. Clinical Cancer Research. 21(8). 1877–1887. 129 indexed citations
17.
Biernacka, Kalina, Li Zeng, Amit Bahl, et al.. (2013). Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2. Endocrine Related Cancer. 20(5). 741–751. 71 indexed citations
18.
Sen, Chandan K., et al.. (2005). Activated Akt expression in breast cancer: Correlation with p53, Hdm2 and patient outcome. European Journal of Cancer. 41(7). 1017–1025. 42 indexed citations
19.
20.
Perks, Claire M. & D.C. Wathes. (1996). Expression of mRNAs for insulin-like growth factor binding proteins-2, -3 and -4 in the ovine ovary throughout the oestrous cycle. Journal of Endocrinology. 151(2). 241–249. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiji Saibara Breakdown of academic impact, for papers by Vittorio Colantuoni Breakdown of academic impact, for papers by Norman C.W. Wong Breakdown of academic impact, for papers by Elvira Haas Breakdown of academic impact, for papers by Tomomi Fujisawa Breakdown of academic impact, for papers by Zemin Yao Breakdown of academic impact, for papers by Samuele De Minicis Breakdown of academic impact, for papers by Salvatore Mancuso Breakdown of academic impact, for papers by Giulia Chiesa Breakdown of academic impact, for papers by Mary G. Sorci‐Thomas
Rankless by CCL
2026